Free tool
FAERS Monitor: Tpoxx
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 214518 or its brand name (Tpoxx, Tecovirimat). Reports on generic versions are filed under their own applications.
Reports
104
Serious
50
48% of reports
Hospitalization
23
Death reported
14
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug resistance19
- headache14
- nausea14
- fatigue12
- diarrhoea10
- acute kidney injury6
- alanine aminotransferase increased6
- decreased appetite5
- off label use5
- abdominal pain4
- dizziness4
- drug ineffective4
- skin lesion4
- vomiting4
- abdominal discomfort3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 3 |
| 2021 | 1 |
| 2022 | 10 |
| 2023 | 42 |
| 2024 | 35 |
| 2025 | 7 |
| 2026 | 6 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,055 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| drug resistanceSignal | 19 | 149.7 | 99.7 | 2,661 |
| skin lesionSignal | 4 | 29.5 | 11.3 | 84 |
| alanine aminotransferase increasedSignal | 6 | 19.8 | 9.1 | 89 |
| acute kidney injurySignal | 6 | 7.9 | 3.6 | 30 |
| headacheSignal | 14 | 4.5 | 2.8 | 36 |
| decreased appetiteSignal | 5 | 4.4 | 1.9 | 10 |
| abdominal discomfort | 3 | 3.6 | 1.2 | 3 |
| nauseaSignal | 14 | 3.6 | 2.2 | 24 |
| abdominal painSignal | 4 | 3.5 | 1.3 | 5 |
| diarrhoeaSignal | 10 | 3.1 | 1.7 | 13 |
| fatigueSignal | 12 | 3.1 | 1.8 | 16 |
| vomiting | 4 | 1.7 | 0.7 | 1 |
| dizziness | 4 | 1.6 | 0.6 | 0 |
| off label use | 5 | 1.2 | 0.5 | 0 |
| drug ineffective | 4 | 0.6 | 0.2 | 1 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.